84 completed, 18 unknown, 10 terminated, 4 active not recruiting. 63 Phase 2, 37 Phase 1, 35 Phase 3, 2 Not applicable.
Follow Mitoxantrone Hydrochloride: new trials by email Literature Review of Mitoxantrone Hydrochloride trials Research Report on Mitoxantrone Hydrochloride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Venetoclax, Azacitidine, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 70 | 2023-07-25 | 2026-09-17 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
| Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm Cladribine, Cytarabine, Gemtuzumab Ozogamicin - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 66 | 2018-09-14 | 2023-08-30 |
| Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor - Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia | Phase 2 | Completed | University of Washington | 50 | 2016-12-30 | 2022-03-08 |
| Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS Cladribine, Cytarabine, Decitabine - Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 28 | 2016-11-17 | 2020-03-17 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Cladribine, Cyclosporine, Cytarabine - Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Completed | University of Washington | 30 | 2016-09-22 | 2021-11-08 |
| Alvocidib Biomarker-driven Phase 2 AML Study Alvocidib, Cytarabine, Mitoxantrone - Acute Myeloid Leukemia | Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 104 | 2016-03-14 | 2023-11-15 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
| Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Cytarabine, Mitoxantrone Hydrochloride, Selinexor - Acute Myeloid Leukemia | Phase 1 | Completed | University of Chicago | 25 | 2015-10-07 | 2020-04-08 |
| Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Sirolimus, Mitoxantrone, Etoposide - Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 39 | 2015-10-07 | 2026-05-29 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
| Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Cytarabine, Dexamethasone - Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | Phase 3 | Active not recruiting | Children's Oncology Group | 158 | 2015-07-21 | 2026-02-18 |
| Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia mitoxantrone hydrochloride, etoposide, cytarabine - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Alice Mims | 23 | 2015-05-18 | 2023-06-15 |
| Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab - Recurrent B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 669 | 2014-12-17 | 2026-10-21 |
| Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia ixazomib, mitoxantrone hydrochloride, etoposide - Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Completed | Case Comprehensive Cancer Center | 30 | 2014-10-08 | 2018-12-13 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Cladribine, Cytarabine, Filgrastim - Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 199 | 2014-01-23 | 2020-01-10 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | University of Southern California | 10 | 2013-03-06 | 2018-03-30 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia CPI-613, cytarabine, mitoxantrone hydrochloride - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | Wake Forest University Health Sciences | 67 | 2013-01-01 | 2018-07-03 |
Showing 20 of 122. Sign in to see all of them.
Leukemia, Myeloid, Acute (51) · Leukemia (42) · Congenital Abnormalities (23) · Leukemia, Erythroblastic, Acute (22) · Leukemia, Monocytic, Acute (22) · Leukemia, Myelomonocytic, Acute (22) · Leukemia, Megakaryoblastic, Acute (21) · Lymphoma (19) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Prostatic Neoplasms (14) · Myelodysplastic Syndromes (11) · Lymphoma, Non-Hodgkin (10) · Lymphoma, Follicular (9) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, Large-Cell, Immunoblastic (9)
National Cancer Institute (NCI) (15) · Fred Hutchinson Cancer Center (9) · Children's Oncology Group (8) · European Organisation for Research and Treatment of Cancer - EORTC (8) · Masonic Cancer Center, University of Minnesota (4) · Case Comprehensive Cancer Center (3) · Lymphoma Trials Office (3) · Memorial Sloan Kettering Cancer Center (3) · GERCOR - Multidisciplinary Oncology Cooperative Group (2) · German CLL Study Group (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (2) · Lederle Laboratories (2) · Medical Research Council (2) · NCIC Clinical Trials Group (2) · OHSU Knight Cancer Institute (2)
United States (79) · Canada (17) · United Kingdom (17) · France (15) · Germany (14) · Italy (12) · Australia (11) · Belgium (11) · Netherlands (10) · Austria (8) · Puerto Rico (8) · Czechia (5) · New Zealand (5) · Portugal (5) · Switzerland (5)
Judith Karp (4) · Roland Walter (4) · Daniel J. Weisdorf, MD (3) · Sergio Amadori, MD (3) · Alan K. Burnett, MD, FRCP (2) · Anjali Advani (2) · Anna Halpern (2) · Franco Mandelli, MD (2) · Leona A. Holmberg, MD, PhD (2) · Patrick J. Stiff, MD (2) · Philip D. Bonomi, MD (2) · Richard Aplenc, MD, MSCE (2) · Roel Willemze, MD, PhD (2) · Ruth Pettengell, MD (2) · Alan S. Gamis, MD, MPH (1)
PMID 36815378, PMID 37267439, PMID 38295280, PMID 42085603, PMID 34596937, PMID 40294366, PMID 11857298, PMID 12239143, PMID 12419743, PMID 12947070, PMID 15339678, PMID 15353542, PMID 15637138, PMID 15761020, PMID 16136166, PMID 16333838, PMID 16888080, PMID 16932345, PMID 17039234, PMID 17315155, PMID 17339189, PMID 17407135, PMID 17611565, PMID 18025439, PMID 18299450, PMID 18349405, PMID 18467731, PMID 18782306, PMID 19291085, PMID 19349545, PMID 19638218, PMID 19826132, PMID 20038732, PMID 20071660, PMID 20209646, PMID 20378563, PMID 20407035, PMID 20421533, PMID 21131038, PMID 21231927, PMID 21239698, PMID 21502546, PMID 21504050, PMID 21623761, PMID 21766293, PMID 22571691, PMID 22649108, PMID 22680764, PMID 22733022, PMID 23321258
P30CA015704 (5), U01CA070095 (5), U10CA180886 (5), P30CA043703 (4), P30CA006973 (3), U10CA098543 (3), P01CA075606 (2), P30CA012197 (2), 2004 (1), 2008 (1), N01CM00032 (1), N01CM00100 (1), N01CM62202 (1), N01CM62203 (1), N01CM62206 (1)